• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Adare Pharma Solutions

    PCI Pharma Services

    Alcami

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Cytovance Biologics

    Aphena Pharma Solutions

    Reed-Lane

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Effective Post Market Supplier Strategy for Combination Products

    Combinations are typically designed, developed and maintained under a robust contract manufacturing process

    Effective Post Market Supplier Strategy for Combination Products
    Related CONTENT
    • Asymchem
    • Mogene
    • Softweb Solutions
    • Vetio Animal Health
    • Risk-Based Monitoring
    Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services06.13.19
    This article will serve to answer the following questions:
    • How should combination product companies monitor impacts of product, process or regulatory changes?
    • What technical documentation and supporting processes should be in place for effective post market product management?
    • How are post market issues such as Corrective and Preventive Actions (CAPAs), Complaints and Change Controls managed? Who is responsible for evaluation of these systems and how does this get managed with multiple suppliers?

    This article is targeted for companies that have existing combination products on the market or are prepping their quality management systems to be compliant with FDA Final Rule 21 CFR Part 4. If you have a product under development, aside from meeting all requirements of 21 CFR Part 4, the FDA will want to see a post market maintenance plan for the product after it is launched, especially when there are multiple contract suppliers involved. This article will serve as support for products at both stages. Combination products, which is a combination of a drug or biologic with a device delivery constituent part, are typically designed, developed and maintained under a robust contract manufacturing process. It is quite difficult to do an “all-in-one” combination product that is made by a single organization. For example, it is not uncommon for combination product companies to have the following types of contract suppliers:
    •  A Contract Development Organization (CDO) is responsible to design and develop the device constituent parts and is typically responsible to build the Design History File (DHF). In some cases, these organizations are also contracted to maintain the DHF for the lifetime of the product.
    • A Drug Supplier (DS) is responsible to supply the bulk drug to the CMO (as defined below). 
    • A Contract Manufacturing Organization (CMO) is responsible to receive design transfer requirements from the CDO and receive the drug substance from the DS to manufacture the combination product. A CMO can also be an affiliated company within the Product Owner’s global organization.
    • A Human Factors (HF) organization is contracted to perform Human Factors activities under Design Validation.
    • A Lab Supplier (LS) organization is contracted to perform product testing. The services can be for raw material, in-process and final product testing. A LS can also be an affiliated company within the Product Owner’s global organization.

    It is important to note that the Product Owner, not the CMO, is responsible for the overall quality of the product. The FDA holds the Product Owner responsible for any issues that occur in the field and during operations. This is why it is important to set up a robust quality management system that evaluates, qualifies and monitors contract supplier performance. So now, let’s walk through the device centric 21 CFR Part 4 requirements applicable to supplier performance and control.

    21 CFR Part 820.20 Management Responsibilities
    Quality Objectives must be set by the Product Owner under this element. It’s a good practice to include measurable quality objectives for these suppliers to ensure they are being monitored. Quality Metrics are set based on the organization’s quality objectives. Management Reviews must be set to review the progress and effectiveness of the quality management system which includes contract suppliers managed under that system. Here are some tips to consider:
    • Track contract supplier effectiveness via metrics reviewed during management review.
    • Quality Metrics should include key performance indicators specific to product performance and supplier related objectives.
    • Supplier CAPAs should be monitored and evaluated for trends and timeliness of closure.
    • Assign resources to be aware of regulatory changes which may affect the product and suppliers. Review these changes during management review.
    • It is recommended to have Management Reviews at least twice per year with dedicated resource to track progress of open items and supplier performance.

    Regarding Quality Planning, how will the suppliers collaborate for Complaint investigations, CAPA investigations, and Change Control updates post product launch? When the product is on the market, the Product Owner needs to ensure the right subject matter experts are evaluating and reviewing these documents. Quality Planning encourages product safety and efficacy by having supplier relations set in place to ensure all parties are aware of their responsibilities. Here are some tips to consider:
    • Create a shared Post Market Quality Planning Document with the critical contract suppliers that explains the manufacturing process. The plan will indicate who manufactures, who tests, who maintains the DHF, etc. for product post market surveillance.
    • The Product Owner and critical suppliers (e.g. CMO) should sign off on the Quality Planning Document.
    • The Quality Planning Document is an expanded document of the Quality Agreement. If the Quality Agreement is a shared agreement between suppliers, it can be used in place of the Quality Planning Document provided it is sufficient enough to cover all quality planning activities stated above.
    • If your product includes software, explain high level software integration and product lifecycle management in the Quality Planning Document.

    21 CFR Part 820.30 Design Control
    There are a number of items that need to be in place for product post market maintenance. Design Controls is the only element in the medical device quality system regulations that links product development to commercialization. The DHF that is released at the final design review prior to product launch continues to be a living file throughout the lifetime of the product. This also includes the product Risk Management File. The DHF requirements must be referenced for all major and critical CAPAs, Complaint Investigations, Deviations, Change Controls and any other product related events. Below are some items that should be considered:
    • Who is maintaining the DHF for product lifecycle? Is the CDO contracted for this or does the Product Owner have an internal subject matter expert?
    • Updates to procedures, drawings, specifications, test methods, etc. must be tracked and in the same version between Product Owner, DHF holder, and CMO.
    • Is there an expert on risk management assigned to product lifecycle management? Risk documents must be maintained and can only be done by subject matter experts.
    • Software Lifecycle Management:
    -Software Life Cycle Process must be developed per FDA design control requirements;
    -Configuration management must be established and connected to the Change Control system of the overall product and maintained throughout product lifecycle;
    -DHF is required for the combination product of the device AND the associated connected software as part of that system;
    -Software requirements should be established at the design inputs high level requirements (top down) and then cascaded down into the software requirements;
    -Major/critical software changes must be evaluated for impact to the DHF. A subject matter expert will need to be in place for this (contract supplier organization or internal employee); and
    -Software Risk Management Planning must serve as an input to the overall Product Risk Management Planning during product development and provides continual feedback for post market maintenance.

    21 CFR Part 820.50 Purchasing Controls
    The Product Owner is responsible to select, evaluate, qualify and monitor all suppliers. The monitoring system should be risk based. For example, it is expected for critical suppliers to have the most stringent controls requiring audits and other means of continuous monitoring. This element of the regulations stresses that suppliers must not implement any changes without knowledge of the Product Owner and that these changes must be evaluated for potential impact to the product. In fact, changes must be verified or validated prior to implementation to ensure the change had no impact to the safety or efficacy of the product. This rule prevents Product Owners from completely relying on their suppliers without monitoring them. The following are also factors that should be considered under this element:
    • Quality Agreements must be established with major and critical suppliers and they must address post market maintenance of the product (e.g. managing of CAPAs, Complaints, Changes, Deviations, etc.)
    • How will Deviations and CAPAs be investigated?
    • How will Complaints be managed and investigated?
    The FDA can issue 483s to Product Owner based on inadequate investigations of supplier.  Accordingly, ensure that you have appropriately skilled auditors doing supplier assessments. For example, only assign pharmaceutical auditors to perform drug related audits and device auditors to perform a design control audit.
    • Determine the extent of control of 21 CFR Part 4 and ensure that your suppliers’ quality management systems are in compliance.
    • As stated under the Design Control discussion above, the purchase order system should be designed to prevent building with components with incorrect versions.

    21 CFR Part 820.100 Corrective and Preventive Action (and discussion on Complaints)
    Managing CAPAs can get complicated when there are multiple suppliers that have input into product distribution. Purchasing Controls are a very important system that will help manage the CAPA process that includes a thread of suppliers. Verification and/or validation of executed CAPA plans must be performed. Companies can leverage the quality metrics process to help monitor suppliers for continuous improvement and CAPA verification. Here are some tips on CAPAs and Complaints:
    •  Post market risk assessment must be established to receive, investigate and mitigate investigations, CAPAs and Complaints between suppliers.
    •  All quality system indicators (failures, audit findings, complaints, etc.) should connect to the Product Owner’s CAPA system for major or critical issues determined by the Risk Management Process.
    • As stated above, outline responsibilities in the Quality Technical Agreement and Quality Planning Document that is shared between suppliers.
    • Remember, for combination products, all CAPAs MUST be verified or validated for effectiveness. FDA has issued 483s to combination product sites that fell short on this requirement.
    •  Ensure the right subject matter experts are assigned to determine root cause. Ineffective root causes lead to repeat issues in the field.
    •  It is recommended that Software, Design and Product Residual Risks identified during the development phase should be added as potential complaint errors to monitor in the field.
    •  Which agency receives the complaint? The root cause directs you to which agency needs to be notified (sometimes both).
    • Complaints/Recall Facilitator must be familiar with current FDA Guidance on Postmarket Safety Reporting for Combination Products.
    •  Remember that the Product Owner (not the Supplier) is responsible to notify the FDA for safety reporting.
    In conclusion, we can see how important it is to have a robust Post Market Quality Plan that explains the relationship between contract suppliers, with respect to commercial operations. During development, the Product Owner may have contract suppliers that are only used during the development phase.

    However, the Post Market Quality Plan should only include suppliers contracted for commercial operations. For companies getting ready to launch their product, this document should be developed during the Design transfer phase as it will be an excellent aide during the FDA PAI. For companies with legacy products, the plan will help in routine FDA inspections.

    In sum, post market surveillance of combination products that are managed under multiple contract suppliers can be maintained with the right systems in place provided that the Product Owner is fully aware of what is required. Subject matter experts must be in place to ensure the product is properly maintained throughout the lifetime of the product. Follow the tips above and you will be on your way to a successful state of compliance.


    Lori-Ann Woodard CBA, CQE, CSQE
    Lachman Consultant Services

    Lori-Ann Woodard, is Director of Medical Devices in the Compliance Practice at Lachman Consultants. With more than 20 years of experience, Ms. Woodard delivers expertise in the creation and implementation of Quality Management Systems for Medical Devices including Software as a Medical Device (SaMD), and for Combination Products. She is an expert with extensive knowledge and application of the Code of Federal Regulations and International Standards in the Medical Device, Combination Product, and Pharmaceutical industries.
    Related Searches
    • contract manufacturing organization
    • fda
    • software
    • events
    Suggested For You
    Asymchem Asymchem
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Risk-Based Monitoring Risk-Based Monitoring
    The Orphan Promise The Orphan Promise
    Enable Injections Enters into Partnership with Sanofi Enable Injections Enters into Partnership with Sanofi
    Cytek Biosciences Achieves ISO 9001:2015 certification Cytek Biosciences Achieves ISO 9001:2015 certification
    Lilly Lilly's CYRAMZA Gains Fifth Indication
    Nitrosamines Nitrosamines
    The Manufacturing Revolution In Medicine The Manufacturing Revolution In Medicine
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    Lachman Consultants Names Compliance Services VP Lachman Consultants Names Compliance Services VP
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review

    Related FDA Watch

    • Solid Dosage/Creams/Ointments
      Recent Advances in Solid Dispersion Technologies

      Recent Advances in Solid Dispersion Technologies

      Improving the bioavailability and therapeutic efficiency of poorly soluble drugs.
      José L. Toro, Directory, Lachman Consultants 01.27.21

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20


    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20

    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      Inquiring Minds Want to Know, Just Ask FDA

      Inquiring Minds Want to Know, Just Ask FDA

      What you need to know prior to submission
      Michelle Ryder, Lachman Consultant 04.01.20


    • Regulatory Affairs
      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.
      Amy Schutte, Senior Associate, Lachman Consultant Services 03.04.20

    • Regulatory Affairs
      Inactive Ingredients: Where Guidance Needs to Meet Data

      Inactive Ingredients: Where Guidance Needs to Meet Data

      Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.
      Sharif Ahmed, Lachman Consultants Services 10.15.19

    • Regulatory Affairs
      Continuous Manufacturing and its Regulatory Challenge

      Continuous Manufacturing and its Regulatory Challenge

      ...
      José L. Toro, PhD, Lachman Consultants 09.16.19


    • QA/QC | Validation
      Considerations for Analytical Method Validation Lifecycle Controls

      Considerations for Analytical Method Validation Lifecycle Controls

      ICH is set to implement new regulatory guidance dedicated to analytical method development
      Paul Mason, PhD, Lachman Consultants 07.15.19

    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19


    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19

    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login